At Canexia Health, we make high-quality cancer genomic information accessible and affordable with our clinically-validated assays, informatics, and support.
Only a small percentage of cancer patients receive genomic biomarker testing that could match them with targeted treatments demonstrated to improve outcomes. We pair the latest advances in oncology with machine learning to provide cancer professionals with the insights needed to make targeted treatment decisions for their patients.
Tailor treatment decisions based on somatic mutations in your patient’s tumor.
A minimally invasive option for biopsy, Follow It can also be used to monitor cancer progression or investigate treatment resistance.
Rapid, cost-effective, and clinically actionable, Fusions allows you the flexibility to isolate and interrogate relevant fusions.
Make more informed treatment decisions by using detailed results for therapeutic recommendations and expertly curated clinical trials information provided in our comprehensive reporting software.
Conduct world-leading mutation assays for cancer patients, right from your laboratory. Our cloud-based analytics platform allows partner labs access to our proprietary informatics software suite covering the full stack of molecular and computational quality assurance, genome analytics, mutation interpretation, and report generation.
“We have found the FIND-IT assay to be a reliable, quick and cost-effective tool for identifying driver mutations in fixed tissue samples from across Australia. This has had direct implications for identifying patients suitable for targeted therapies, especially those with lung cancer, colorectal cancer and melanoma. However, the scope of the test is such that there is also interest in the panel for patients with a variety of other cancers, including breast and endometrial cancers.” Professor Graeme Suthers, Sonic Genetics
September 22, 2020
We recently conducted a cost savings analysis for healthcare organizations interested in bringing liquid biopsy testing in-house. We discovered that, compared to outsourcing, in-house liquid biopsy testing with an actionable circulating tumor DNA (ctDNA) panel would enable healthcare organizations to attain substantial cost savings -- $2.7M per 1,000 cancer patients.
September 16, 2020
Funding comes after the company meets key milestones with new collaborations and studies, product enhancements, and reimbursement progress.
August 27, 2020
DeciBio interviewed Canexia Health's Brady Davis to discuss how Canexia Health and Project ACTT (Access to Testing and Treatment) are leveraging Canexia’s tech transfer platform and liquid biopsy test, Follow IT, to bridge the gap between the Canadian cancer community and molecular testing during the COVID-19 pandemic.
Canexia Health’s clinically-validated and cost-effective assays, informatics, and support offer a complete end-to-end solution, from mutation identification to auto-generated clinical reports.